Clinical Trials Browser

Tretinoin × 1 year × Clear all

NCT07504458 2026-04-16

QUATRO-APL

Phase 3 Recruiting

Other hematologic neoplasm

Hematologic Diseases, Leukemia, Neoplasms, Leukemia, Promyelocytic, Acute, Hematologic Neoplasms

NCT06536413 2026-04-03

ATRA

Phase 1/2 Recruiting

Multiple Myeloma

NCT05345002 2026-02-20

All-Trans Retinoic Acid (ATRA) Plus PD-1 Inhibition in Recurrent IDH-Mutant Glioma

Phase 2 Recruiting

Astrocytoma, Glioma, Oligodendroglioma

NCT04919369 2026-02-13

All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06358677 2026-02-13

FACE

Phase 2 Recruiting

Neoplasm Metastasis

NCT07348107 2026-01-16

ATARI-PDAC

Phase 1 Not yet recruiting

Neoplasm Metastasis

NCT04241276 2026-01-07

STARPAC2

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT07296445 2025-12-29

LATITUDE

Phase 3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Leukemia, Promyelocytic, Acute

NCT04113863 2025-12-18

ATRA

Phase 2 Terminated

Breast Neoplasm Female

NCT01409161 2025-12-17

Tretinoin and Arsenic Trioxide With or Without Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia

Phase 2 Recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT06439888 2025-12-01

LySATRA

Phase 1/2 Recruiting

Other solid neoplasm

Oligometastatic Disease

NCT06706401 2025-11-18

Lysari

Phase 3 Recruiting

Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Oropharyngeal Neoplasms

NCT06731140 2025-11-17

Resilire

Phase 2 Recruiting

HER2 Negative Breast Cancer

NCT02712905 2025-11-04

An Open-Label, Dose-Escalation/Dose-Expansion Safety Study of INCB059872 in Subjects With Advanced Malignancies

Phase 1/2 Terminated

116 enrolled 36 charts

MyeloidOther hematologic neoplasmThoracic

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Primary Myelofibrosis, Small Cell Lung Carcinoma

NCT04303169 2025-10-27

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT06528769 2025-09-30

Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma

Phase 2 Recruiting

Leiomyosarcoma, Sarcoma

NCT07187505 2025-09-23

Venetoclax Combined With ATRA and ATO in Hyperleukocytic Acute Promyelocytic Leukemia

Phase NA Active not recruiting

Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

NCT04305041 2025-08-29

KEYMAKER-U02

Phase 1/2 Completed

Parkinson Disease 4, Autosomal Dominant Lewy Body, Melanoma

NCT05999812 2025-05-25

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

Phase 2 Active not recruiting

Gastrointestinal

Colorectal Neoplasms